Cagrilintide vs Retatrutide: What’s the Difference
The one-line answer
Cagrilintide and retatrutide are both unapproved, investigational peptides from different companies, at different stages of the FDA process. Cagrilintide is already part of a filed application, but only as one half of a combination product, CagriSema, that Novo Nordisk submitted in December 2025. Retatrutide has not been filed at all; Eli Lilly has said it expects to submit in the first quarter of 2027. Neither compound is approved for any use today.
Regulatory status, side by side
| Compound | Status | Filing stage | Developer |
|---|---|---|---|
| Cagrilintide | Investigational, not approved on its own | Filed Dec 2025, as part of the CagriSema combination; under FDA review | Novo Nordisk |
| Retatrutide | Investigational, not approved | Not yet filed; Lilly has said it plans to file in Q1 2027 | Eli Lilly |
See our full breakdown of retatrutide’s FDA timeline and our cagrilintide identity and FDA status guide for the sourcing behind each row.
Different molecules, different companies
Cagrilintide is a long-acting, chemically modified analogue of human amylin, built on a pramlintide-like backbone. Retatrutide is a different class of molecule, developed separately by Eli Lilly. They come from two competing companies, are studied in different trial programs, and were designed around different starting biology. Being discussed in the same online conversations does not mean they are chemically related or interchangeable.
Why they get compared
Cagrilintide and retatrutide are grouped together because both are next-generation, injectable peptides in the same broad wave of obesity and metabolic research that produced already-approved drugs like semaglutide and tirzepatide. Cagrilintide’s FDA filing, as part of CagriSema, is further along procedurally than retatrutide’s, since Lilly has not yet submitted an application for retatrutide at all. That difference in filing stage is a fact about paperwork and process, not a statement about which molecule works better; head-to-head trial data comparing the two does not exist.
What this means for research use
Peptryn sells both cagrilintide and retatrutide as laboratory research materials only, the same way it sells everything else in its catalog. We do not sell CagriSema or semaglutide, and we do not give dosing or administration guidance for anything we sell. See the cagrilintide product page and the retatrutide product page for current specifications, and our guide to peptide legality for how research-use sales are treated.
Common questions
Is cagrilintide stronger than retatrutide?
That is a claim about therapeutic effect, and Peptryn does not make effect claims about any compound it sells. What can be stated factually is the regulatory record: cagrilintide is part of a filed application under FDA review, and retatrutide has not been filed.
Will cagrilintide be approved before retatrutide?
No one can say that with certainty. Cagrilintide’s combination filing is further along in the process, but a pending filing does not ensure an approval date, and the FDA can request more information at any point. Retatrutide has not been filed at all as of this writing.
Can I buy CagriSema or semaglutide from Peptryn?
No. Peptryn’s catalog does not include CagriSema or semaglutide. See our cagrilintide listing and retatrutide listing for the compounds we do sell, supplied strictly for laboratory research.
Related: What is cagrilintide? · Retatrutide’s FDA approval status · Retatrutide vs semaglutide and tirzepatide · Buying retatrutide for research · Popular peptides
For laboratory research use only. Not for human or veterinary use, and not a drug, food, dietary supplement or cosmetic. You must be 21 or older to buy.
